Ftse Mib
34.249,77
0,91%
DAX
18.161,01
1,32%
S&P 500
5.099,96
1,02%
NASDAQ Composite
15.927,90
2,03%
Bitcoin
63.707,63
0,47%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Assistenza
Home Investire Azioni U.S.A. NASDAQ Galmed Pharmaceuticals Ltd (GLMD) Galmed Pharmaceuticals Ltd (GLMD) Notizie

Galmed Pharmaceuticals Ltd

GLMD
0,3916
-0,0009 (-0,23%)
27 Apr 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
04/4/202423:06PRNUSGalmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F..
15/3/202414:00PRNUSGalmed Announces Grant of New Patent for the Combination of..
14/2/202420:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202422:15EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
30/11/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
22/11/202322:48EDGAR2Form POS AM - Post-Effective amendments for registration..
20/11/202322:37EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/11/202322:32PRNUSGalmed Announces a delay in the initiation of its Primary..
01/11/202321:15EDGAR2Form POS AM - Post-Effective amendments for registration..
26/9/202314:51EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
26/9/202314:30PRNUSGalmed Announces Allowance of New Patent for Aramchol for..
22/9/202322:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/9/202322:05PRNUSGalmed Pharmaceuticals Announces Receipt of Nasdaq Minimum..
21/9/202313:30EDGAR2Form 6-K/A - Report of foreign issuer [Rules 13a-16 and..
20/9/202322:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/9/202322:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/8/202322:43EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/8/202322:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/8/202322:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/7/202316:12EDGAR2Form SC 13G - Statement of acquisition of beneficial..
18/7/202315:25EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
18/7/202315:23EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
14/7/202315:44EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/7/202315:30PRNUSGalmed Pharmaceuticals Announces Pricing of $7 Million..
13/7/202323:08EDGAR2Form F-1/A - Registration statement for certain foreign..
12/7/202323:29EDGAR2Form F-1/A - Registration statement for certain foreign..
10/7/202314:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/7/202314:00PRNUSGalmed to employ OnKai's disruptive Artificial Intelligence..
28/6/202314:40EDGAR2Form FWP - Filing under Securities Act Rules 163/433 of free..
28/6/202314:37EDGAR2Form F-1/A - Registration statement for certain foreign..
01/6/202314:00PRNUSGalmed Pharmaceuticals Reports First Quarter 2023 Financial..
09/5/202313:00PRNUSGalmed Announces Initiation of a Clinical Development..
Apertura: 0,3949 Min: 0,367 Max: 0,3949
Chiusura: 0,3925

La tua Cronologia

NASDAQ
GLMD
Galmed Pharmaceuticals
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network